Shuttle Pharmaceuticals Holdings Inc (SHPH) Stock Price, Quote & News

Company Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HD...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 403 4212

Website: www.shuttlepharma.com

Address:

401 Professional Drive, Suite 260, Gaithersburg, United States

Vikingsstrade Oct. 3 at 7:30 PM

$SMX $SHPH $RGC $NCI Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

MoonCowBoy Oct. 3 at 12:34 AM

$FGEN $SMX $SHPH $RGC :

0 · Reply

Tyranic Oct. 2 at 11:41 PM

$SHPH More continuation…after tomorrow’s pull back… Totally in if we get it… Otherwise,

0 · Reply

1Spartantrade1 Oct. 2 at 6:35 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $RAPT $FGEN $SMX $SHPH 🔥

0 · Reply

MOOSEN Oct. 1 at 11:01 PM

$SHPH GUESS SO. BEEN PLAYING SWINGERS. BESOS.

0 · Reply

i_like_bb_stock Oct. 1 at 3:12 PM

$SHPH added a few off the 3.60 double bottom from a few weeks ago, long due for a run

1 · Reply

lookout408 Sep. 29 at 3:57 PM

$SHPH

0 · Reply

Invest2Create Sep. 26 at 3:40 PM

The typhoon here in the Philippinesvis over and the power is on. But my two picks, $CISO and $SHPH, haven’t been performing as expected, going sideways instead of starting good uptrends. So, I’ve sold both and will work on screens some more as we dry out and clean up here.

1 · Reply

i_like_bb_stock Sep. 24 at 7:15 PM

$SHPH took a position 6 month daily is ripe for a breakout moved big pre split

0 · Reply

WallStVisions Sep. 24 at 3:26 PM

XPON Everyone is chasing what already ran hasn’t moved yet but it has everything: • Lithium + energy exposure • Tight float • Reversal chart structure When momentum rotates, this could lead. $PALI $SHPH $IPDN $AGBA $HTCR

0 · Reply

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Jun 24, 2025, 4:10 PM EDT - 3 months ago

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Jun 20, 2025, 3:55 PM EDT - 3 months ago

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Jun 12, 2025, 12:00 PM EDT - 4 months ago

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Jun 12, 2025, 8:30 AM EDT - 4 months ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Jun 4, 2025, 4:01 PM EDT - 4 months ago

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

May 15, 2025, 4:45 PM EDT - 5 months ago

Shuttle Pharma Provides Corporate Update

May 8, 2025, 4:01 PM EDT - 5 months ago

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Apr 21, 2025, 4:15 PM EDT - 5 months ago

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 10, 2025, 4:01 PM EDT - 6 months ago

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Mar 13, 2025, 4:10 PM EDT - 7 months ago

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 12, 2025, 9:24 AM EDT - 7 months ago

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025, 6:20 AM EDT - 7 months ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Feb 26, 2025, 10:45 AM EST - 7 months ago

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Jan 7, 2025, 9:00 AM EST - 9 months ago

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Nov 26, 2024, 9:00 AM EST - 11 months ago

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 13, 2024, 5:00 PM EST - 11 months ago

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Oct 29, 2024, 9:05 PM EDT - 1 year ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 28, 2024, 4:05 PM EDT - 1 year ago

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 4, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Aug 26, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 14, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Jun 18, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

May 22, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 14, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Apr 23, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Mar 22, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Mar 5, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Feb 13, 2024, 8:00 AM EST - 1 year ago

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Jan 23, 2024, 4:30 PM EST - 1 year ago

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 8, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Dec 11, 2023, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Nov 30, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 14, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Sep 25, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Sep 13, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

Sep 11, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

Aug 15, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

Aug 3, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

May 26, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

May 17, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

Mar 22, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

Mar 15, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

Mar 9, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

Vikingsstrade Oct. 3 at 7:30 PM

0 · Reply

MoonCowBoy Oct. 3 at 12:34 AM

$FGEN $SMX $SHPH $RGC :

0 · Reply

Tyranic Oct. 2 at 11:41 PM

$SHPH More continuation…after tomorrow’s pull back… Totally in if we get it… Otherwise,

0 · Reply

1Spartantrade1 Oct. 2 at 6:35 PM

0 · Reply

MOOSEN Oct. 1 at 11:01 PM

$SHPH GUESS SO. BEEN PLAYING SWINGERS. BESOS.

0 · Reply

i_like_bb_stock Oct. 1 at 3:12 PM

$SHPH added a few off the 3.60 double bottom from a few weeks ago, long due for a run

1 · Reply

lookout408 Sep. 29 at 3:57 PM

$SHPH

0 · Reply

Invest2Create Sep. 26 at 3:40 PM

1 · Reply

i_like_bb_stock Sep. 24 at 7:15 PM

$SHPH took a position 6 month daily is ripe for a breakout moved big pre split

0 · Reply

WallStVisions Sep. 24 at 3:26 PM

0 · Reply

vcaelum Sep. 23 at 10:44 PM

$IBG POTENTIAL PM RUNNER Just had merger news, after merger valuation for IBG (only 10% of the total value when combined) expected to be around $22-34.3m, while current MC is only around $6M. So it should be trading around $2.37 - $3.7 per share Float around 4.65m (dilution tracker) or 5.83m (webull). OS around 9.28m. CLEAN TICKER no active dilution / offering filings 26/9 will undergo 1:5 RS Just went to $1.5 PM before being brought down with the rest of the market $SHPH $LAC $YAAS $STI

1 · Reply

MarkMcLain Sep. 22 at 3:55 PM

$SHPH is making moves now.

0 · Reply

The_Titan_Traders Sep. 22 at 3:15 PM

$SHPH BREAK OF 5.00 SENDS HARD

0 · Reply

dbr_island Sep. 22 at 3:13 PM

$SHPH there it goes… Im telling you 🚨COCP🚨 is my next APVO WATCH AND LEARN LIKE👇

0 · Reply

The_Titan_Traders Sep. 22 at 3:12 PM

Taking some $SHPH

0 · Reply

Highstak3s Sep. 22 at 1:24 PM

$SHPH adding dips here....

0 · Reply

STAFWINS Sep. 19 at 12:46 PM

$APVO Winners next week $ALLR $SHPH $INM $ARMP

0 · Reply

Moneymastermind99 Sep. 19 at 11:44 AM

$TGL closed at $1.27 (+3.25%) with heavy churn (3.2M vol ≈ float). Strong defense at $1.20, resistance $1.42. Shorts remain high, setting up squeeze potential on any catalyst. 🚀Near-term likely consolidates $1–1.50 unless fresh news sparks breakout to $2+.🚀 Watch volume — >3M favors upside, <2M risks fade. Other low-float runners in play: $VWAV, $SHPH, $HCDI, $COSM. Expect volatility — tight risk mgmt is key. #Stocks #DayTrading

0 · Reply

Jonsbr Sep. 18 at 4:21 PM

$BREA $SHPH

0 · Reply

Jonsbr Sep. 18 at 4:02 PM

$BREA $SHPH 🫢😉

0 · Reply

Jonsbr Sep. 18 at 3:56 PM

$BREA 😉 $SHPH

0 · Reply

PLATINUM_TRADES Sep. 18 at 1:49 PM

$SHPH Adds! Break $2.50 please 🔑🔑

1 · Reply

Market Cap	4.80M
Revenue (ttm)	0.00
Net Income (ttm)	-9.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	103,000
Avg Vol	66,936
Day's Range	N/A - N/A
Shares Out	1.07M
Stochastic %K	90%
Beta	-1.01
Analysts	Strong Buy
Price Target	N/A